WO2004110349A3 - Epitopes de lymphocytes t utiles en tant que vaccin contre le virus du syndrome respiratoire aigu severe (sras) et en tant qu'outils diagnostiques et procedes d'identification associes - Google Patents

Epitopes de lymphocytes t utiles en tant que vaccin contre le virus du syndrome respiratoire aigu severe (sras) et en tant qu'outils diagnostiques et procedes d'identification associes Download PDF

Info

Publication number
WO2004110349A3
WO2004110349A3 PCT/US2004/015026 US2004015026W WO2004110349A3 WO 2004110349 A3 WO2004110349 A3 WO 2004110349A3 US 2004015026 W US2004015026 W US 2004015026W WO 2004110349 A3 WO2004110349 A3 WO 2004110349A3
Authority
WO
WIPO (PCT)
Prior art keywords
sars
epitopes
methods
cell epitopes
sequences
Prior art date
Application number
PCT/US2004/015026
Other languages
English (en)
Other versions
WO2004110349A2 (fr
Inventor
Morten Nielsen
Ole Lund
Claus Lundegaard
Peder Worning
Soren Buus
Soren Brunak
Sune Justesen
Christina Sylvester-Hvid
Gustav A Roder
Kasper Lamberth
Original Assignee
Siga Technologies Inc
Morten Nielsen
Ole Lund
Claus Lundegaard
Peder Worning
Soren Buus
Soren Brunak
Sune Justesen
Christina Sylvester-Hvid
Gustav A Roder
Kasper Lamberth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siga Technologies Inc, Morten Nielsen, Ole Lund, Claus Lundegaard, Peder Worning, Soren Buus, Soren Brunak, Sune Justesen, Christina Sylvester-Hvid, Gustav A Roder, Kasper Lamberth filed Critical Siga Technologies Inc
Priority to CA002525778A priority Critical patent/CA2525778A1/fr
Publication of WO2004110349A2 publication Critical patent/WO2004110349A2/fr
Priority to IL171924A priority patent/IL171924A0/en
Publication of WO2004110349A3 publication Critical patent/WO2004110349A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Selon un premier aspect, l'invention concerne des épitopes de lymphocytes T situés dans le génome du virus du syndrome respiratoire aigu sévère (SRAS). Plus particulièrement, il existe 180 épitopes de peptides linéaires de classe I et 200 épitopes linéaires de classe II provenant du génome du virus du SRAS. Selon un deuxième aspect, l'invention concerne des variants de ces séquences. Selon un troisième aspect, l'invention concerne un procédé de prédiction de ces séquences à partir de données du génome et de validation des prédictions de manière expérimentale. Selon un quatrième aspect, l'invention concerne des compositions comprenant ces épitopes, destinées à être utilisées dans un vaccin et à induire une réaction des lymphocytes T chez un sujet, ou en tant qu'outil diagnostique.
PCT/US2004/015026 2003-05-14 2004-05-14 Epitopes de lymphocytes t utiles en tant que vaccin contre le virus du syndrome respiratoire aigu severe (sras) et en tant qu'outils diagnostiques et procedes d'identification associes WO2004110349A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002525778A CA2525778A1 (fr) 2003-05-14 2004-05-14 Epitopes de lymphocytes t utiles en tant que vaccin contre le virus du syndrome respiratoire aigu severe (sras) et en tant qu'outils diagnostiques et procedes d'identification associes
IL171924A IL171924A0 (en) 2003-05-14 2005-11-13 T cell epitopes useful in a severe acute respiratory syndrome (sars) virus vaccine and as diagnostic tools and methods for identifying same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200300725 2003-05-14
DKPA200300725 2003-05-14

Publications (2)

Publication Number Publication Date
WO2004110349A2 WO2004110349A2 (fr) 2004-12-23
WO2004110349A3 true WO2004110349A3 (fr) 2006-03-23

Family

ID=33547529

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/015026 WO2004110349A2 (fr) 2003-05-14 2004-05-14 Epitopes de lymphocytes t utiles en tant que vaccin contre le virus du syndrome respiratoire aigu severe (sras) et en tant qu'outils diagnostiques et procedes d'identification associes

Country Status (3)

Country Link
CA (1) CA2525778A1 (fr)
IL (1) IL171924A0 (fr)
WO (1) WO2004110349A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009055005A2 (fr) * 2007-10-23 2009-04-30 The Regents Of The University Of Colorado Inhibiteurs compétitifs de l'expression de chaînes invariantes et/ou d'une liaison d'un clip ectopique
US8828929B2 (en) 2008-11-28 2014-09-09 Nof Corporation Cytotoxic T cell epitope peptide for SARS coronavirus, and use thereof
WO2018102317A1 (fr) * 2016-11-29 2018-06-07 The Regents Of The University Of California Modulation de p53 pour le traitement du cancer
EP3892297A1 (fr) * 2020-04-09 2021-10-13 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptides et combinaisons de peptides à utiliser en immunothérapie contre une infection par le sars-cov-2 (covid-19)
CN111440229B (zh) * 2020-04-13 2021-08-03 中国人民解放军军事科学院军事医学研究院 新型冠状病毒t细胞表位及其应用
EP4138907A1 (fr) * 2020-04-20 2023-03-01 The General Hospital Corporation Composition immunogène de coronavirus à épitopes ayant un score de réseau élevé
CN116056722A (zh) * 2020-04-20 2023-05-02 Nec奥克尔姆内特公司 Sars-cov-2疫苗
WO2021228853A1 (fr) * 2020-05-11 2021-11-18 Ose Immunotherapeutics Vaccin contre le virus sras-cov
KR20210155366A (ko) * 2020-06-15 2021-12-22 한국과학기술원 신규한 코로나 바이러스의 에피토프 및 이의 용도
WO2022026921A1 (fr) * 2020-07-30 2022-02-03 Repertoire Immune Medicines, Inc. Identification et utilisation d'épitopes de lymphocytes t dans la conception d'approches diagnostiques et thérapeutiques associées à la covid-19
WO2022067062A1 (fr) * 2020-09-24 2022-03-31 Epivax, Inc. Développement rapide d'un vaccin prophylactique à large spectre pour le sars-cov-2 à l'aide d'un système d'administration d'antigène à médiation par phage
US20240123054A1 (en) * 2021-02-22 2024-04-18 Joseph COTROPIA Coronavirus antigens and epitopes and proteins that bind thereto
EP4319726A1 (fr) * 2021-04-08 2024-02-14 Ramot at Tel-Aviv University Ltd. Nanovaccins destinés au traitement de maladies virales
WO2022268916A2 (fr) 2021-06-23 2022-12-29 Ose Immunotherapeutics Vaccin peptidique pan-coronavirus
CN113666989B (zh) * 2021-08-12 2023-08-29 中国科学技术大学 新型冠状病毒cd8+ t细胞表位肽及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] "putative orflab polyprotein (SARS coronavirus)", accession no. NCBI Database accession no. (NP828849) *
XU Z ET AL: "The R Protein of SARS-CoV: Analyses of Structure and Function Based on Four Copmlete Genome Sequences of Isolates BJ101-BJ104.", GENOMICS PROTEOMICS BIOINFORMATICS, vol. 1, no. 2, May 2003 (2003-05-01), pages 155 - 165, XP001182393 *

Also Published As

Publication number Publication date
WO2004110349A2 (fr) 2004-12-23
IL171924A0 (en) 2006-04-10
CA2525778A1 (fr) 2004-12-23

Similar Documents

Publication Publication Date Title
WO2004110349A3 (fr) Epitopes de lymphocytes t utiles en tant que vaccin contre le virus du syndrome respiratoire aigu severe (sras) et en tant qu'outils diagnostiques et procedes d'identification associes
WO2004074455A3 (fr) Variants de la region fc
DE602004024542D1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
HK1210627A1 (en) Preparing crude biological estracts using protease, suitable for preparing cdna cdna
DE50202328D1 (de) Amidofunktionelle aminopolydiorganosiloxane
DK1476541T3 (da) Cytokin (zcytor17-ligand)
AU2003294533A1 (en) Molecular methods and compositions for detecting and quantifying respiratory viruses
WO2007092645A3 (fr) Nouvelles combinaisons d'inhibiteurs du vhc et méthodes
WO2003070187A3 (fr) Proteines de fusion de mycobacterium tuberculosis
DK1399590T3 (da) Happier kortlægning
WO2005051313A3 (fr) Procedes et reactifs pour le traitement, la prevention et le diagnostic d'infection par le bunyavirus
NO20044398L (no) Fotokatalysatorer inneholdende titanoksyd, samt fremgangsmate og anvendelse derav
WO2004091524A3 (fr) Vaccins contre des virus des voies respiratoires
DE602004027767D1 (de) Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara
ATE542810T1 (de) Verfahren zur herstellung von 3,5-di-omikron-acyl-2-fluor-2-c-methyl-d-ribono gamma-lacton
NO20060420L (no) 2-aminobenzoylderivater
EP1312673A4 (fr) Procede de protection d'informations personnelles
DE69936774D1 (de) Strukturproteine des virus, welches die pankreas-krankheit bei fischen verursacht, und ihre verwendungen
AU2003255611A1 (en) Novel antiretroviral sulpholipids extracted from spirulinae, method for obtaining same, compositions containing same and use thereof as inhibitors of the hiv virus reverse transcriptase
DK1664102T3 (da) Isoleret photoprotein mtclytin, samt dets anvendelse
WO2004029835A3 (fr) Systeme et procede d'association de differents types de contenus multimedia
AU2003285775A1 (en) Method for identifying, analyzing and/or cloning nucleic acid isoforms
WO2005037855A3 (fr) Epitopes de lymphocytes t convenant pour un vaccin contre la peste et comme outils de diagnostic, et procede d'identification correspondant
DE60224280D1 (de) Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis
FI20020375A (fi) Menetelmä viruksen kaltaisten partikkeleiden (VKP) tuottamiseksi, plasmidikonstrukti sekä menetelmän käytöt

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 171924

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2525778

Country of ref document: CA

122 Ep: pct application non-entry in european phase